NEW YORK, NY / ACCESS Newswire / March 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers ...

Merck & Co. is leveraging March 4’s International HPV Awareness Day for a marketing campaign in China, lighting up landmark buildings in four megacities in the hopes of reigniting demand amid ...

In addition, the current report stated Merck's "decision to temporarily pause shipments of GARDASIL/GARDASIL 9 into China ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

March 11 (Reuters) - A federal judge ruled in favor of Merck (MRK.N), opens new tab in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... He does something that looks really harsh about China, it's not harsh at all. So China then comes back, I mean ...

Merck & Co., Inc. (NYSE:MRK) is a pharmaceutical company that Cramer commonly discusses on his show. Its shares are down by 31.7% over the past year primarily due to troubles in China over the ...

The decision made public on Tuesday by U.S. District Judge Kenneth Bell in Charlotte, North Carolina covers more than 200 ...

Merck & Co's efforts to diversify its cancer pipeline beyond immunotherapy blockbuster Keytruda have taken a big step forward with a wide-ranging alliance with China's Kelun-Biotech that spans ...

Germany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s strategic tie-up with the China-based multinational tech ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...